EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy

Romina Marone iD, Emmanuelle Landmann iD, Anna Devaux iD, Rosalba Lepore iD, Denis Seyres iD, Jessica Zuin iD, Thomas Burgold iD, Corinne Engdahl iD, Giuseppina Capoferri iD, Alessandro Dell'Aglio iD, Clément Larrue iD, Federico Simonetta iD und 22 weitere

Journal of Experimental Medicine · 2023

DOI: 10.1084/jem.20231235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2023. Verfasst von Romina Marone und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Interleukin-3 Receptor alpha Subunit, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council under the Europan Union's Horizon 2020 research and innovation programme, NOMIS Foundation, Lotte and Adolf Hotz-Sprenger Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted eradication of transformed or otherwise dysregulated cells using monoclonal antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric antigen receptor (CAR) cells is very effective for hematologic diseases. Unlike the breakthrough progress achieved for B cell malignancies, there is a pressing need to find suitable antigens for myeloid malignancies. CD123, the interleukin-3 (IL-3) receptor alpha-chain, is highly expressed in various hematological malignancies, including acute myeloid leukemia (AML). However, shared CD123 expression on healthy hematopoietic stem and progenitor cells (HSPCs) bears the risk for myelotoxicity. We demonstrate that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage. Transplantation of genome-edited HSPCs could enable tumor-selective targeted immunotherapy while rebuilding a fully functional hematopoietic system. We envision that this approach is broadly applicable to other targets and cells, could render hitherto undruggable targets accessible to immunotherapy, and will allow continued posttransplant therapy, for instance, to treat minimal residual disease (MRD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-3 Receptor alpha SubunitLeukemia, Myeloid, AcuteHumansEpitopesImmunotherapyHematopoietic Stem CellsImmunotherapy, Adoptive

Substanzen

Interleukin-3 Receptor alpha SubunitEpitopes

Autor:innen und Institutionen

  • Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
  • Transplantation Immunology and Nephrology, Basel University Hospital, Basel, Switzerland.
  • Cimeio Therapeutics AG , Basel, Switzerland.
  • Ridgeline Discovery GmbH , Basel, Switzerland.
  • Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, and Swiss Cancer Center Leman, Geneva, Switzerland.
  • Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.

ORCID-Profile: Romina Marone, Emmanuelle Landmann, Anna Devaux, Rosalba Lepore, Denis Seyres, Jessica Zuin, Thomas Burgold, Corinne Engdahl, Giuseppina Capoferri, Alessandro Dell'Aglio, Clément Larrue, Federico Simonetta, Julia Rositzka, Manuel Rhiel, Geoffroy Andrieux, Danielle N Gallagher, Markus S Schröder, Amélie Wiederkehr, Alessandro Sinopoli, Valentin Do Sacramento, Anna Haydn, Laura Garcia-Prat, Christopher Divsalar, Anna Camus, Liwen Xu, Lorenza Bordoli, Torsten Schwede, Matthew Porteus, Jérôme Tamburini, Jacob E Corn, Toni Cathomen, Tatjana I Cornu, Stefanie Urlinger, Lukas T Jeker

Förderung

  • European Research Council under the Europan Union's Horizon 2020 research and innovation programme
  • NOMIS Foundation
  • Lotte and Adolf Hotz-Sprenger Stiftung
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Helen Hay Whitney Foundation
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Marone, R., Landmann, E., Devaux, A., Lepore, R., Seyres, D., Zuin, J., Burgold, T., Engdahl, C., Capoferri, G., Dell'Aglio, A., Larrue, C., Simonetta, F., Rositzka, J., Rhiel, M., Andrieux, G., Gallagher, D. N., Schröder, M. S., Wiederkehr, A., Sinopoli, A., …, & Jeker, L. T. (2023). Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20231235

Vancouver

Marone R, Landmann E, Devaux A, Lepore R, Seyres D, Zuin J, et al. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. Journal of Experimental Medicine. 2023. doi:10.1084/jem.20231235

BibTeX
@article{Marone2023,
  author = {Marone, Romina and Landmann, Emmanuelle and Devaux, Anna and Lepore, Rosalba and Seyres, Denis and Zuin, Jessica and Burgold, Thomas and Engdahl, Corinne and Capoferri, Giuseppina and Dell'Aglio, Alessandro and Larrue, Clément and Simonetta, Federico and Rositzka, Julia and Rhiel, Manuel and Andrieux, Geoffroy and Gallagher, Danielle N and Schröder, Markus S and Wiederkehr, Amélie and Sinopoli, Alessandro and Do Sacramento, Valentin and Haydn, Anna and Garcia-Prat, Laura and Divsalar, Christopher and Camus, Anna and Xu, Liwen and Bordoli, Lorenza and Schwede, Torsten and Porteus, Matthew and Tamburini, Jérôme and Corn, Jacob E and Cathomen, Toni and Cornu, Tatjana I and Urlinger, Stefanie and Jeker, Lukas T},
  title = {Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy},
  journal = {Journal of Experimental Medicine},
  year = {2023},
  doi = {10.1084/jem.20231235}
}
Kostenlos starten →